Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Auxilium Adopts 'Poison Pill' Plan After $1.41B Offer from Endo

September 17, 2014 10:21 am | News | Comments

The board of Auxilium Pharmaceuticals Inc. has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker. Read more...

TOPICS:

Australia Promises $6.4M to Fight Ebola

September 17, 2014 10:17 am | News | Comments

Australia announced on Wednesday it will immediately provide an additional 7 million Australian dollars ($6.4 million) to help the international response to the Ebola outbreak in West Africa. Read more...              

TOPICS:

Relmada in MOA Agreement With MSKCC

September 16, 2014 3:47 pm | News | Comments

Relmada Therapeutics Inc. announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of LevoCap ER. Read more...         

TOPICS:
Advertisement

TapImmune Releases Interim Data on Phase 1 Cancer Trial

September 16, 2014 3:39 pm | News | Comments

TapImmune Inc. reported that analysis of the interim data from the first 13 patients in a Phase 1 clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of five naturally processed folate receptor alpha Class II antigenic epitopes. Read more...

TOPICS:

Amarin Committed to Completing Cardiovascular Outcomes Study

September 16, 2014 3:34 pm | News | Comments

Amarin Corp. announced its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial) cardiovascular outcomes study. Read more...                 

TOPICS:

Mylan to Begin Phase 3 Trials on Key Generics

September 16, 2014 3:28 pm | News | Comments

Mylan Inc. announced it is initiating Phase 3 clinical trials for its generic version of GlaxoSmithKline's Advair Diskus and its insulin analog to Sanofi's Lantus.  Read more...                   

TOPICS:

Nektar Says FDA Clears Constipation Drug Movantik

September 16, 2014 2:41 pm | News | Comments

Nektar Therapeutics said Tuesday that U.S. regulators approved its drug Movantik, a once-per-day treatment for constipation caused by opioid painkillers. Movantik, or naloxegol, is approved for adults who have chronic pain that is not caused by cancer. Read more...

TOPICS:

Lilly, AstraZeneca Team Up on Alzheimer's Drug

September 16, 2014 11:43 am | News | Comments

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing. Read more...      

TOPICS:
Advertisement

Bayer, Orion Initiate Phase 3 Prostate Cancer Trial

September 16, 2014 10:26 am | News | Comments

Bayer HealthCare and Orion Corp. have begun to enroll patients in a Phase 3 trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment of patients with prostate cancer. Read more...

TOPICS:

Novo Nordisk's Insulin Shows Long-Term Efficacy in Children, Adolescents

September 16, 2014 10:19 am | News | Comments

Novo Nordisk announced new data from the BEGIN YOUNG 1 trial investigating once-daily Tresiba (insulin degludec) versus insulin detemir, both in combination with bolus insulin aspart in a 52-week trial in children and adolescents with type 1 diabetes. Read more...

TOPICS:

Northwest Bio's Cell Therapy Named 'Promising Innovative Medicine'

September 16, 2014 10:04 am | News | Comments

An innovative cell therapy for cancer has become the first designated "promising" as part of a scheme to get medicines to patients quicker. The medicine, named DCVax-L, has been developed by U.S.-based pharmaceutical company Northwest Biotherapeutics Inc. Read more...

TOPICS:

UN: Nearly $1B Needed Now to Stop Ebola

September 16, 2014 9:45 am | by John Heilprin and Krista Larson | News | Comments

The World Health Organization is warning that the number of Ebola cases in West Africa could double every three weeks. The estimate comes Tuesday as the U.N. health agency said the cost of containing the deadly virus has risen to nearly $1 billion. Read more...

TOPICS:

Allergan Agrees to Move Forward With Meeting

September 16, 2014 6:41 am | by The Associated Press | News | Comments

Allergan and Pershing Square are agreeing on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold special shareholders meeting, as Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker. Read more...

TOPICS:

NY Suing Actavis to Halt Alzheimer's Drug Swap

September 15, 2014 7:39 pm | by Michael Virtanen | News | Comments

New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from discontinuing its drug widely used to treat Alzheimer's patients, arguing the company is illegally driving patients to its newer patented drug to avoid losses. Read more...

TOPICS:

Merck Osteoporosis Drug Meets Primary Endpoint in Phase 3

September 15, 2014 3:49 pm | News | Comments

Merck announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Merck’s investigational once-weekly cathepsin K inhibitor. Read more...           

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading